ClinicalTrials.gg

TargetBeta

BRAF

B-Raf proto-oncogene, serine/threonine kinase · also BRAF1, BRAF-1 · Mitogen-activated protein kinase kinase kinases

5 programs in company-led studies act on BRAF, from 5 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
regorafenibruleBayerphase 4404 runningABL1, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEKChEMBL
tovorafenibruleDay One Biopharmaceuticalsphase 383 runningARAF, RAF1ChEMBL
BRAF V600E Inhibitor HLX208Fosun Pharmaphase 2127 running–the company's pipeline
belvarafenibruleHanmi Pharmaceuticalphase 264 runningARAF, RAF1ChEMBL
claturafenibPfizerphase 121 running–the company's pipeline

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.